Novartis’ Ilaris fails in late-stage COVID-19 trial
pharmaphorum
NOVEMBER 6, 2020
Novartis noted that the results from this trial do not affect Ilaris’ licensed indications or other trials and the safety profile was comparable to placebo plus standard of care. Novartis is also working with Molecular Partners to develop therapies based on genetically engineered proteins known as DARPins.
Let's personalize your content